Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Accured Expenses: 2015-2025

Historic Change in Accured Expenses for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to -$543,000.

  • Editas Medicine's Change in Accured Expenses fell 153.50% to -$543,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 1418.94%. This contributed to the annual value of $11.6 million for FY2024, which is 182.52% up from last year.
  • Latest data reveals that Editas Medicine reported Change in Accured Expenses of -$543,000 as of Q3 2025, which was down 193.94% from $578,000 recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Change in Accured Expenses registered a high of $17.1 million during Q4 2024, and its lowest value of -$9.6 million during Q1 2021.
  • Over the past 3 years, Editas Medicine's median Change in Accured Expenses value was $1.0 million (recorded in 2024), while the average stood at $1.6 million.
  • Per our database at Business Quant, Editas Medicine's Change in Accured Expenses surged by 1,905.82% in 2021 and then crashed by 288.79% in 2024.
  • Quarterly analysis of 5 years shows Editas Medicine's Change in Accured Expenses stood at $5.3 million in 2021, then soared by 108.42% to $11.0 million in 2022, then slumped by 62.77% to $4.1 million in 2023, then soared by 319.01% to $17.1 million in 2024, then tumbled by 153.50% to -$543,000 in 2025.
  • Its Change in Accured Expenses stands at -$543,000 for Q3 2025, versus $578,000 for Q2 2025 and $1.7 million for Q1 2025.